The xiaflex market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...

More than a decade after earning FDA approval for Xiaflex as a nonsurgical treatment option for Dupuytren’s contracture, Endo is debuting its first-ever branded TV commercial in the indication.

Steve, a patient with Dupuytren’s contracture (curled fingers), gets to hold hands with his wife again in Endo’s first-ever commercial touting how its decade-old Xiaflex can treat the condition.

March 12, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX ® (collagenase clostridium histolyticum, or CCH ...